Pay in 4 interest-free payments of $5.62 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
According to a clinical research plan updated by the company in early 2024, Lilly will conduct multiple Phase 3 clinical trials for Retatrutide over the next three years, with targeted indications primarily including obesity, chronic kidney disease, and type 2 diabetes
Patient variability is significant in managing expectations
These trials are recruiting participants in multiple countries including the United States, Australia, and several European nations
Who Is a Good Candidate for Treatment
US$ 20.36
US$ 29.50
US$ 24.61
US$ 26.04
US$ 22.11
US$ 21.99
US$ 23.35
US$ 29.62
